Rilmenidine, an innovative antihypertensive agent, is an orally active, selectiveI1imidazoline receptoragonist. Rilmenidine is analpha 2-adrenoceptoragonist. Rilmenidine inducesautophagy. Rilmenidine acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na⁺/H⁺antiport. Rilmenidine modulates proliferation and stimulates the proapoptotic proteinBaxthus inducing the perturbation of the mitochondrial pathway andapoptosisin human leukemic K562 cells^[1][2][3].

Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors^[1].
Rilmenidine (25-100 μM; 24 hours) inhibits K562 cell proliferation^[2].

Rilmenidine-treated N171-82Q mice (i.p.; 4-times a week) displays significant improved forelimb grip strength and all limbs grip strength from 12 to 22 weeks of age^[3].
Rilmenidine decreases levels of mutant huntingtin^[3].

180.25

C₁₀H₁₆N₂O

54187-04-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.